InGen BioSciences Inks Distribution Pact with Quidel and Diagnostic Hybrids in France

InGen BioSciences has signed exclusive distribution agreements in France with two major international players in the field of diagnostics in vitro, Quidel and Diagnostic Hybrids.

“These exclusive partnerships enable Ingen BioSciences meet the unmet needs of French biologists in the early detection of infectious diseases, bacterial or viral, to bring a pregnancy test effective and fast, and thus assist physicians in personalized care to their patients,” says Isabelle Buckle , CEO of InGen BioSciences.

Quidel Corporation (San Diego, California, USA) is a leader in rapid diagnostic tests. He chose the expertise of InGen BioSciences for distribution in France, of 14 of its tests showing a result in three to 15 minutes on seven different parameters in the fields of infectious diseases and reproductive health.

“The Quidel's product portfolio, marketed under the brand name of QuickVue, currently includes diagnostic tests for influenza, respiratory syncytial virus, Strep A, Infectious Mononucleosis, of Helicobacter pylori, Chlamydia and testing of pregnancy,” said Douglas Bryant, CEO of Quidel Corporation. “We are delighted with the opportunities we offer the expertise of InGen BioSciences for marketing our rapid diagnostic reagents in France.”

Diagnostic Hybrids (Athens, Ohio, USA) is a pioneer in the development of molecular virology tests, Quidel integrated. Diagnostic Hybrids has signed a strategic partnership with InGen Biosciences for marketing its tests Direct Fluorescent Antibody and Culture (DFA) that allow physicians to identify eight major respiratory viruses, including influenza virus, Influenza A H1N1, Metapneumovirus and three families of herpes virus (Herpes Simplex Virus, Cytomegalovirus, Varicella-zoster virus).

The group InGen BioSciences is a company flexible, responsive, customer-centric and in search of best innovations (in products and services) to meet the needs of doctors and biologists for their patients; InGen BioSciences develops and markets diagnostic kits in vitro and advanced controllers for clinical use (proprietary or licensed).